Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-03
2006-01-03
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000
Reexamination Certificate
active
06982250
ABSTRACT:
The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the morality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotide sequences and the FGF-CX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
REFERENCES:
patent: 2002/0001825 (2002-01-01), Itoh
patent: 2365869 (2002-02-01), None
patent: 5301893 (1993-11-01), None
patent: WO 00/54813 (2000-09-01), None
patent: WO 01/07595 (2001-02-01), None
patent: WO 01/31008 (2001-05-01), None
patent: WO 01/68854 (2001-09-01), None
patent: WO 01/72957 (2001-10-01), None
patent: WO 01/92522 (2001-12-01), None
patent: WO 02/02625 (2002-01-01), None
patent: WO 02/24234 (2002-03-01), None
patent: WO 02/36732 (2002-05-01), None
patent: WO 02/46424 (2002-06-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 29, No.: 37, pp. 8509-8517.
Jeffers et al. A Novel Human Fibroblast Growth Factor Treats Experimental Intestinal Inflammation. 2002, Gastroenterology, vol. 123, pp. 1151-1162.
Pickering, et al. (1997). “Fibroblast Growth Factor-2 Potentiates Vascular Smooth Muscle Cell Migration to Platelet-Derived Growth Factor” and “Upregulation of α2β1Integrin and Disassembly of Actin Filaments”Cir. Res.80:627-637.
Klein, et al. (1995). “Differential Modulation of Cell Phenotype by Different Molecular Weight Forms of Basic Fibroblast Growth Factor: Possible Intracellular Signaling by the High Molecular Weight Forms”J. Cell Biol.Apr.; 129(1):233-43. (ABSTRACT).
U.S. application No. 60/161,162, filed Oct. 22, 1999, Itch, et al.
U.S. Application No. 60/124,460, filed Mar. 15, 1999, Manning et al.
Bange et al. (2002).Cancer Res 62: 840-847.
Bikfalvi et al. (1997)Endocrine Reviews 18: 26-45.
Kirikoshi et al. (2000).Biochemical and Biophysical Res Comm 274: 337-343.
Ohmachi et al. (2000).Biochemical and Biophysical Res Comm 277: 355-360.
Wong et al. (2001).Am J of Medical Genetics 102: 282-285.
International Search Report for PCT/US02/19400, mailed Jun. 4, 2003.
Altschul, et al. (1990). “Basic local alignment search tool.”J. Mol Biol 215(3): 403-10.
Basilico and Moscateli (1992). “The FGF family of growth factors and oncogenes.”Adv Cancer Res 59: 115-65.
Danilenko (1999). “Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor.”Toxicol Pathol 27(1): 64-71.
Gasparini (1999). “The rationale and future potential of angiogenesis inhibitors in neoplasia.”Drugs 58(1): 17-38.
GenBank Accession No.: A58788 (Mar. 6, 1998).
GenBank Accession No.: AA232729 (Nov. 27, 1996).
GenBank Accession No.: AA236522 (Nov. 27, 1996).
GenBank Accession No.: AAF00049 (Jun. 22, 2000).
GenBank Accession No.: AAF80597 (Aug. 27, 2001).
GenBank Accession No.: AB012615 (Sep. 8, 1999).
GenBank Accession No.: AB020858 (May 21, 1999).
GenBank Accession No.: AF091434 (Jun. 22, 2000).
GenBank Accession No.: AI272876 (Nov. 18, 1998).
GenBank Accession No.: AI272878 (Nov. 18, 1998).
GenBank Accession No.: BAB03265 (Jul. 26, 2000).
GenBank Accession No.: E05822 (Sep. 29, 1997).
GenBank Accession No.: P36364 (Nov. 1, 1997).
GenBank Accession No.: P54130 (Oct. 16, 2001).
GenBank Accession No.: P98070 (Oct. 16, 2001).
GenBank Accession No.: S82023 (May 5, 2002).
Gerwins, et al. (2000). “Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis.”Crit Rev Oncol/Hematol 34(3): 185-94.
Grisham (1994). “Oxidants and free radicals in inflammatory bowel disease.”Lancet 344(8926): 859-61.
Klint and Claesson-Welsh (1999) “Signal transduction by fibroblast growth factor receptors”Front. Biosci. 4: d165-177.
Koga, et al. (1999). “Characterization of a novel member of the FGF family, XFGF-20, inXenopus laevis.” Biochem Biophys Res Commun 261(3): 756-65.
La Rocca, et al. (1990). “Suramin: prototype of a new generation of antitumor compounds.”Cancer Cells 2(4): 106-15.
Li, et al. (1997). “Activation of FGF receptors by mutations in the transmembrane domain.”Oncogene 14(12): 1397-406.
Lichtiger, et al. (1994). “Cyclosporine in severe ulcerative colitis refractory to steroid therapy.”N Engl J Med 330(26): 1841-5.
Lorenzi, et al. (1996). “FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement.”Proc Natl Acad Sci U S A 93(17): 8956-61.
Matsumoto-Yoshitomi, et al. (1997). “Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis.”Int J Cancer 71(3): 442-50.
Miyakawa, et al. (1999). “A hydrophobic region locating at the center of fibroblast growth factor- 9 is crucial for its secretion.”J Biol Chem 274(41): 29352-7.
Miyake, et al. (1998). “Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family.”Biochem Biophys Res Commun 243(1): 148-52.
Miyamoto, et al. (1993). “Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property.”Mol Cell Biol 13(7): 4251-9.
Mount (1996). “AT-AC introns: an ATtACk on dogma.”Science 271(5256): 1690-2.
Munkholm, et al. (1994). “Frequency of glucocorticoid resistance and dependency in Crohn's disease.”Gut 35(3): 360-2.
Nakai and Kanehisa (1992). “A knowledge base for predicting protein localization sites in eukaryotic cells.”Genomics 14(4): 897-911.
Naruo, et al. (1993). “Novel secretory heparin-binding factors from human glioma cells. (glia- activating factors) involved in glial cell growth. Purification and biological properties.”J Biol Chem 268(4): 2857-64.
Pearson, et al. (1995). “Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.”Ann Intern Med 123(2): 132-42.
Present, et al. (1999). “Infliximab for the treatment of fistulas in patients with Crohn's disease.”N Engl J Med 340(18): 1398-405.
Revest, et al. (2000). “Fibroblast growth factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequence.”J Biol Chem 275(11): 8083-90.
Santos-Ocampo, et al. (1996). “Expression and biological activity of mouse fibroblast growth factor-9.”J Biol Chem 271(3): 1726-31.
EMBL Database Accession No.: Q9Q1Y71 (May 1, 2000).
EMBL Database Accession No.: Q9UL22 (May 1, 2000).
Szebenyi and Fallon (1999). “Fibroblast growth factors as multifunctional signaling factors.”Int Rev Cytol 185: 45-106.
Wozney, et al. (1988). “Novel regulators of bone formation: molecular clones and activities.”Science 242(4885): 1528-34.
Xu, et al. (1999). “Fibroblast growth factor receptors (FGFRs) and their roles in limb development.”Cell Tissue Res 296(1): 33-43.
Yates, et al. (1997). “Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.”Ann Intern Med 126(8): 608-14.
Jeffers Michael
Lichenstein Henry
Andres Janet
Biswas Naomi S.
CuraGen Corporation
Elrifi Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Methods of prevention and treatment of inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of prevention and treatment of inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of prevention and treatment of inflammatory bowel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556869